Breast Surgery F or more than 50 years, women have sought to enhance or restore the shape and appearance of their breasts with implants. In 1988, saline-filled breast implants were classified by the United States Food and Drug Administration (FDA) as class III devices-thereby requiring manufacturers to submit a premarket approval application to demonstrate the safety and effectiveness of the devices. In 1995, Allergan (Santa Barbara, CA; formerly Inamed) began a long-term prospective study of women implanted with saline-filled implants for breast augmentation or breast reconstruction. FDA approval was granted in 2000, and the devices branded as Natrelle saline-filled breast implants are currently in widespread use in the United States. Large bodies of data now support the safety of breast implants in general, with the main safety concerns being the potential for local complications and the need for secondary surgeries.
postsurgery (augmentation subjects only), subject satisfaction with the implants, and QOL assessments (through 3 years). Upon completion of the 5-year in-office portion of the study, subjects were asked if they wanted to participate in the follow-up study. Subjects agreeing to participate signed a new informed consent form.
Two weeks before the sixth to tenth anniversaries of each subject's implantation surgery, a self-completion survey was sent by mail. The survey encompassed questions regarding reoperation, implant replacement/ removal, breast pain, capsular contracture, implant deflation, and satisfaction with implants. For capsular contracture severity grading, subjects were provided with descriptions of the capsule grades which were later classified with Baker grade scores as follows: grade I (naturally soft), grade II (a little firm but looks normal), grade III (firm and looks abnormal due to capsular contracture), and grade IV (painfully hard and looks abnormal due to capsular contracture). These descriptions, coupled with the previous 5 years of office visits-in which investigators discussed capsular contracture as the predominant implant complication-provide reasonable expectations that subjects would appropriately classify the degree of contracture.
Subjects
The primary inclusion criteria for subjects were female, 18 years of age or older, adequate tissue to cover the implants, and no connective tissue or autoimmune disorders. Exclusion criteria included a medical history precluding suitability for surgery (eg, advanced fibrocystic disease or inadequate breast tissue), a previous history of breast augmentation or reconstruction, pregnancy or breastfeeding, any condition that might constitute an unduly high surgical risk, and psychological characteristics that might be incompatible with the surgical procedure or the implant.
Subjects were classified as either augmentation (hypoplasia, asymmetry, ptosis, aplasia, postlactational involution, or congenital deformity) or reconstruction (mastectomy for breast cancer or prophylactic mastectomy, plus contralateral augmentation if desired to match unilateral reconstructions). Both phases of the study obtained institutional review board approval and written informed consent from the subjects.
Devices
This study included the types of Natrelle saline-filled breast implants that were available in 1995, when the study began. Round implants with smooth (styles 60 or 68) or textured (style 168) surfaces and shaped implants with textured surfaces (styles 163, 363, and 468) were eligible for implantation in the study.
Statistical Analyses
Investigators used standardized case report forms to collect data prospectively before implantation and at scheduled follow-up visits as well as at unscheduled office visits. For those complications assessed with severity ratings, the "very mild" or "mild" severities or Baker grades I or II capsular contracture were not considered to be clinically significant problems, and therefore were not included in the analysis.
To determine the effect of implantation on breast size for augmentation subjects, bra size information was collected pre-and postimplantation. At each follow-up visit, subjects provided ratings of implant satisfaction utilizing a 6-point scale (definitely satisfied, satisfied, somewhat satisfied, somewhat dissatisfied, dissatisfied, or definitely dissatisfied). Subjects independently completed QOL questionnaires containing scales measuring general health concepts, self-and body esteem, and breast-related concepts.
The survey mailed to subjects included severity ratings for breast pain and capsular contracture and yes/no checkboxes for the other safety issues, along with checkboxes for common reasons for reoperation. The same 6-point satisfaction scale from the in-office study was included in the survey.
Kaplan-Meier survivorship was the primary analysis method for the safety data, while frequency distributions were employed for implant satisfaction data and reasons for reoperation and explantation. Descriptive statistics were used for breast size change results, and repeated analysis of variance measures were performed on the QOL results.
RESULTS

Subjects and Surgical Characteristics
A total of 1138 subjects enrolled in the study, consisting of 901 women (1800 implants) who underwent breast augmentation and 237 women (316 implants) who underwent breast reconstruction surgery. Of those 1138 subjects, 1070 (94%) completed the initial 5-year phase.
From the 1070 subjects who completed the in-office initial phase of the study, 88.9% consented to participate in the second 5-year phase. Specifically, 89.2% (781 of 876) augmentation subjects and 87.6% (170 of 194) reconstruction subjects enrolled in the mail-in survey portion of the study. At year 10, the surveys were completed by 91.4% of breast augmentation subjects (714 of 781) and 85.9% of reconstruction subjects (146 of 170).
Demographic data revealed that most subjects were white, married, and attended college ( Table 1 ). The median age was 32 years for augmentation subjects and 47 years for reconstruction subjects. The implants used in augmentation subjects were most commonly round and were inserted submuscularly via a periareolar or inframammary incision; the implants used in reconstruction subjects were more frequently shaped and inserted submuscularly via the mastectomy scar (Table 2) . Almost all of the reconstruction implants and two-thirds of the augmentation implants had a textured surface. Pocket irrigation with antibiotic or betadine solutions was common, and the vast majority of the implants were filled within the manufacturer recommended fill volume (80.0%) or less than 10% above the recommended fill volume (13.8%).
Safety
The data collected by physicians during in-office visits showed that through 5 years, the most common complications for augmentation subjects were breast pain (17.0%), wrinkling (13.7%), asymmetry (12.2%), and implant palpability/visibility (12.1%; Table 3 ). The most common complications for reconstruction subjects through 5 years were asymmetry (39.0%), capsular contracture (35.7%), implant palpability/visibility (27.1%), and wrinkling (24.6%). The risk of implant deflation through 5 years was 6.8% for augmentation subjects and 7.5% for reconstruction subjects.
The risk of reoperation (secondary surgical procedure to the breast) through 5 years was 25.9% for augmentation and 44.5% for reconstruction, with the most common reasons for augmentation reoperation being deflation or capsular contracture, and the most common reasons for reconstruction reoperation being capsular contracture or asymmetry. For those subjects who had their implants removed or replaced, the most common reasons for augmentation subjects were patient choice for style or size change (43.4% of 166 explants) or deflation (32.5% of 166 explants), and for reconstruction subjects capsular contracture (31.4% of 70 explants) or patient choice for style or size change (21.4% of 70 explants).
In the more limited safety items assessed at years 6 to 10 through the mailed survey, the most common occurrence for both augmentation and reconstruction subjects through 10 years was reoperation (36.5% and 54.6%, respectively; Table 4 ). Capsular contracture occurred in 20.8% of augmentation subjects and 51.7% of reconstruction subjects through 10 years. Less than one fourth of subjects experienced implant deflation (13.8% for augmentation; 22.5% for reconstruction), with overall implant survivorship (ie, 100% minus the Kaplan-Meier risk rate for by-implant deflation) of 90% after 10 years ( Figure 1) .
The 10-year risk rate for implant replacement/removal was 20.2% and 39.5% for augmentation and reconstruction subjects, respectively. The most common reasons for implant replacement/removal for augmentation subjects were patient choice for style or size change (41.3% of 300 explants) or deflation (33.3% of 300 explants), and for reconstruction subjects were also deflation (32.7% of 104 explants) or patient choice for style or size change (25.0% of 104 explants). Skin hypersensitivity/paresthesia 7.6% (5.9-9.4%) 6.3% (2.9-9.6%) 
Effectiveness
Most subjects who underwent augmentation increased breast size by either 1 (38%) or 2 (49%) cup sizes, with 9% having an increase of 3 cup sizes. The same cup size was maintained by 4% of subjects. The mean QOL scores for augmentation subjects at 3 years postimplantation showed small but statistically significant decreases (worsening) over baseline in the general health concepts assessed by the Short Form 36 (SF-36) and most scales in the Body Esteem Scale (Table  5) . Conversely, statistically significant improvements were seen in the Rosenberg Self-Esteem Scale and the Sexual Attractiveness scale of the Body Esteem Scale. However, aside from the improvement in the Sexual Attractiveness scale, the effect sizes were small, indicating that the changes were unlikely to be clinically significant. Dramatic improvement over baseline (P Ͻ .001) was evident in overall breast satisfaction and satisfaction with breast size, shape, and feel. Overall breast satisfaction for augmentation subjects increased from 3.8% at baseline to 91.9% at 3 years.
Ten years after their implant surgery, more than 85% of women (87.5% augmentation; 86.3% reconstruction) reported being satisfied with their implants (a response of either definitely satisfied, satisfied, or somewhat satisfied; Figure 2 ).
DISCUSSION
Until November 2006, when the FDA approved silicone gelfilled breast implants, saline breast implants were the de facto implant of choice in the United States. Now that the choices have been widened to include silicone implants, the question becomes how saline compares to silicone.
Comparing the 5-year office visit data from this saline study to Spear et al's report 1 of 6-year pivotal study data for Allergan (Natrelle) standard gel implants, we see similar results for the key risk rates of reoperation, implant removal/replacement, and implant rupture/deflation though a higher capsular contracture rate for reconstruction subjects with saline implants (15.9% for silicone versus 35.7% for saline). The real difference between the implant types comes down to the "look and feel" categories. Augmentation subjects with silicone implants had significantly lower rates for wrinkling (1.2% versus 13.7%), implant palpability/ visibility (1.6% versus 12.1%), and asymmetry (3.0% versus 12.2%). Similar trends were seen for reconstruction subjects: wrinkling (10.2% versus 24.6%), implant palpability/visibility (4.1% versus 27.1%), and asymmetry (22.9% versus 39.0%).
The next-generation Natrelle highly cohesive silicone implants fare even better in comparison to the saline implants. 2 For augmentation subjects with highly cohesive implants, the 5-year pivotal study risk rate was less than 1% for wrinkling, implant palpability/visibility, and asymmetry. For reconstruction subjects at 5 years, wrinkling was 2.5%, implant palpability/visibility was 0%, and asymmetry was 9.1%.
These results quantify the commonly held belief espoused in continuing medical education articles on breast augmentation 3-4 and reconstruction 5 that saline implants are more prone to aesthetic complications, 6 An online survey by Young et al 7 of women who had undergone breast augmentation found that silicone implants were significantly more likely than saline implants (P Ͻ .0001) to be rated as "natural feeling." In 2007, the first full year of silicone availability outside of clinical studies, 39.4% of the implantations used silicone implants, 8 up from 18.6% the previous year. 9 This proportion will likely increase over time, given the aesthetic benefits (natural look and feel) of silicone implants. However, saline implants remain a viable choice with their own aesthetic benefits (often a smaller incision).
Patients' satisfaction with saline breast implants is similar to their satisfaction with other cosmetic procedures. Sarwer et al's prospective study 10 of 100 subjects who underwent a variety of cosmetic procedures found that 1 year after the surgical procedure, 70% of participants were "extremely satisfied," a rating of 5 on a 5-point scale. Our saline data also show that 1 year postimplantation, 70% of augmentation subjects rated their satisfaction at the highest level on the scale (definitely satisfied). In comparison, the 1-year proportion of subjects definitely satisfied with their Natrelle silicone implants was 83% for standard silicone and 89% for highly cohesive silicone implants. 11 This greater percentage of subjects who are exceedingly satisfied with their implants is likely related to the natural look and feel benefits described above.
Overall satisfaction rates (including all levels of satisfaction on the rating scale) are extremely high for all of the implant types and remain so over time. The 3 pivotal Natrelle studies showed that satisfaction with augmentation implants was 88% at 10 years for saline implants, 95% at 6 years for silicone implants, 1 and 97% at 5 years for highly cohesive silicone implants. 2 The same studies found that satisfaction with reconstruction implants was similarly high at 86% for saline, 94% for silicone, and 92% for highly cohesive silicone. Therefore, it is not a question of which filler type is better-what is important is for the surgeon and prospective patient to draw upon the body of evidence available to them in order to select the right implant for that particular patient.
CONCLUSIONS
This study demonstrates the long-term safety and effectiveness of Natrelle saline breast implants. The 10 years of data amassed through a prospective clinical study provide a solid foundation of information to facilitate the informed decision process. ◗ 
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